Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Core Insights - Coherus BioSciences has transitioned from marketing biosimilar drugs to focusing solely on its branded drug Loqtorzi (toripalimab) and is now prioritizing the development of its clinical pipeline [1] Company Focus - The company is no longer involved in the marketing of biosimilar drugs and is concentrating on the development of its clinical pipeline [1] Market Position - Coherus BioSciences is currently positioned as a biotech company that trades around significant events such as trial results and NDA/BLA approvals [1]